Shares of Odyssey Therapeutics Inc., a clinical-stage biopharmaceutical company, are expected to begin trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol "ODTX".
The company has priced its initial public offering of 15.50 million shares of its common stock at $18.00 each. The offering, which is scheduled to close on or about May 11, 2026, is expected to rake in gross proceeds of approximately $304 million.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com